Advanced Accelerator Applications: Lutathera supports improved survival for patients with neuroendocrine tumors

Lutathera from Novartis is indicated to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, which include foregut, midgut and handout neuroendocrine tumors in adults. The drug was the focus of a recent presentation World Congress on Gastrointestinal Cancer 2021 where Dr. Jonathan R. Strosberg, presented positive survival data concerning the drug. Strosberg is the head of the Neuroendocrine Tumor... The post Lutathera supports improved survival for patients with neuroendocrine tumors appeared first on Drug Discovery and Development.